{"id":37646,"date":"2025-05-09T13:49:04","date_gmt":"2025-05-09T08:19:04","guid":{"rendered":"https:\/\/dailynewsindia.co.in\/index.php\/2025\/05\/09\/remlife-global-partners-with-jiyayu-lifesciences-to-replace-animal-inputs-in-apis-via-green-chemistry\/"},"modified":"2025-05-09T13:49:04","modified_gmt":"2025-05-09T08:19:04","slug":"remlife-global-partners-with-jiyayu-lifesciences-to-replace-animal-inputs-in-apis-via-green-chemistry","status":"publish","type":"post","link":"https:\/\/dailynewsindia.co.in\/index.php\/2025\/05\/09\/remlife-global-partners-with-jiyayu-lifesciences-to-replace-animal-inputs-in-apis-via-green-chemistry\/","title":{"rendered":"Remlife Global Partners With JiyaYu Lifesciences To Replace Animal Inputs In APIs Via Green Chemistry"},"content":{"rendered":"<div>\n<p><strong>New Delhi [India], May 9: <\/strong>Remlife Global PTE LTD., a Singapore-based subsidiary of BSE-listed Remedium Lifecare Ltd. (India), is pleased to announce a forward-looking partnership with JiyaYu Lifesciences PTE Ltd., a green chemistry technology platform company. This collaboration is focused on replacing animal-origin raw materials in the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates through proprietary fermentation and biocatalyst-based alternatives.<\/p>\n<p>As part of the partnership, JiyaYu will license out fully developed and scalable technologies to Remlife Global on an exclusive basis. These technologies are designed to replace traditional animal-derived steps with sustainable, cost-effective, and regulatorycompliant bioprocesses. Remlife Global will scale up and commercialise these technologies at one or more GMP-compliant contract manufacturing sites across India, Singapore, Malta, Ireland, Belgium, and Italy.<\/p>\n<p><strong>J<\/strong>iyaYu Lifesciences has in turn partnered with a UK-based R&amp;D technology platform specialising in the development of fermentation and biocatalystbased alternatives to animal-origin pharmaceutical inputs. Through this collaboration, JiyaYu gains access to cutting-edge innovations that it will transfer to Remlife Global as fully scalable technologies.<\/p>\n<p>Each technology will be supported by detailed process dossiers and full technology transfer documents, enabling Remlife Global to implement, validate, and scale up the processes at approved GMP manufacturing sites.<\/p>\n<p>These solutions will support Remlife Global\u2019s vision of eliminating dependence on vulnerable and ethically complex supply chains, while capturing new commercial opportunities in global regulated markets.<\/p>\n<p>\u201cOur collaboration with JiyaYu Lifesciences is a transformative move toward building a more ethical, resilient, and sustainable pharmaceutical supply chain.\u201d said Adarsh Munjal.<\/p>\n<p><strong>Financial Outlook<\/strong><\/p>\n<p>Each technology platform has a minimum commercial potential of \u20b950 crore per product, with EBITDA margins estimated between 20% to 25%. Assuming a scale-up of two products per year, cumulative revenue and EBITDA could grow substantially:<\/p>\n<ul>\n<li><strong>FY26: 2 products | \u20b9100 Cr revenue | \u20b920\u201325 Cr EBITDA<\/strong><\/li>\n<li><strong>FY27: 4 products | \u20b9200 Cr revenue | \u20b940\u201350 Cr EBITDA<\/strong><\/li>\n<\/ul>\n<p><strong>Moving Beyond Animal-Based Inputs<\/strong><\/p>\n<p>Remlife Global\u2019s strategic direction is anchored in the belief that the future of pharmaceuticals lies in sustainable, animal-free production. Key reasons for this shift include:<\/p>\n<ul>\n<li><strong>Ethical and ESG Alignment:<\/strong> Modern pharmaceutical companies are under growing pressure to remove animal-based components from their supply chains.<\/li>\n<li><strong>Safety &amp; Quality Control:<\/strong> Fermentation and biocatalyst-based systems offer superior consistency and eliminate the risk of contamination from animal-borne pathogens.<\/li>\n<li><strong>Supply Chain Resilience:<\/strong> Diseases, regulatory shifts, and geopolitical volatility all threaten the availability of animal-derived inputs.<\/li>\n<li><strong>Environmental Benefits:<\/strong> Traditional animal-derived raw materials are linked to high emissions, land use, and water consumption.<\/li>\n<li><strong>Industry Momentum:<\/strong> Leading global pharma firms are rapidly adopting bio-based and cruelty-free technologies in their development pipelines.<\/li>\n<\/ul>\n<p><strong>About Remlife Global PTE LTD.<\/strong><\/p>\n<p>Remlife Global PTE LTD. is the international innovation arm of Remedium Lifecare Ltd. (India), a BSE-listed pharmaceutical company. With a focus on R&amp;D commercialisation and strategic collaborations, Remlife Global is driving the transition to sustainable API Contract manufacturing across multiple global jurisdictions.<\/p>\n<p><strong>Media Contact<\/strong><\/p>\n<p>Adarsh Munjal<\/p>\n<p>Remlife Global PTE LTD.<\/p>\n<p>Email: info@remlife.sg<\/p>\n<p><em>If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi [India], May 9: Remlife Global PTE LTD., a Singapore-based subsidiary of BSE-listed Remedium Lifecare Ltd. (India), is pleased to announce a forward-looking partnership with JiyaYu Lifesciences PTE Ltd., a green chemistry technology platform company. This collaboration is focused on replacing animal-origin raw materials in the manufacturing of active pharmaceutical ingredients (APIs) and advanced&#8230;<\/p>\n<p class=\"more-link-wrap\"><a href=\"https:\/\/dailynewsindia.co.in\/index.php\/2025\/05\/09\/remlife-global-partners-with-jiyayu-lifesciences-to-replace-animal-inputs-in-apis-via-green-chemistry\/\" class=\"more-link\">Read More<span class=\"screen-reader-text\"> &ldquo;Remlife Global Partners With JiyaYu Lifesciences To Replace Animal Inputs In APIs Via Green Chemistry&rdquo;<\/span> &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":37647,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[54],"class_list":["post-37646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business"],"_links":{"self":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/37646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/comments?post=37646"}],"version-history":[{"count":0,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/37646\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media\/37647"}],"wp:attachment":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media?parent=37646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/categories?post=37646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/tags?post=37646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}